Nathalie Auber - Profile and Investment Details

Investor Profile

Nathalie Auber is a Hedge Fund, Venture Capital, Private Equity Firm, Investment Partner based in San Francisco, California, United States with a diverse investment portfolio that includes companies such as ENYO Pharma, Y-mAbs Therapeutics, NuCana, Histogenics, Amplyx Pharmaceuticals, Sorbent Therapeutics, Visen Pharmaceuticals, Versartis, Auris Medical, Aerovate Therapeutics, Medeor Therapeutics, Guavus, Edge Therapeutics, NorthSea Therapeutics, Athira PharmaAscendis Pharma, Audentes Therapeutics, CinCor Pharma, Karuna Therapeutics, Bolt Biotherapeutics, Vestagen Technical Textiles, InCarda Therapeutics, Ziarco, Pionyr Immunotherapeutics, Invitae, AFYX Therapeutics, XyloCor Therapeutics, Natera, LYSOGENE, Neurana Pharmaceuticals, Kiniksa Pharmaceuticals, Aeovian Pharmaceuticals, Principia Biopharma, Innocoll Holdings, Quanta Therapeutics, NuCana BioMed, ZS Pharma, NextCure, ConteXtream, Chiasma, Aclaris Therapeutics, Vera Therapeutics, Checkmate Pharmaceuticals, First Aid Shot Therapy, Apellis Pharmaceuticals, McPhy, Civitas Therapeutics, Crocus Technology, Atsena Therapeutics, Catellus Development Corporation, Rainier Therapeutics, Galera Therapeutics, Gyroscope Therapeutics, VelosBio, Antiva Biosciences, Intrepida Bio, Merus, Mirna Therapeutics, Akouos, Coherus Biosciences, aTyr Pharma, Inozyme, Promedior, Iterum Therapeutics, ObsEva, Dauntless Pharmaceuticals, Spark Therapeutics, Entasis Therapeutics, . Over time, Nathalie Auber has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Nathalie Auber is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Genetics, Wellness, Women Founded, Investment Management, Life Science, Venture Fundraising, Finance, Biotechnology, Drug Development, Genomics, Innovation, Clinical Trials, FinTech, Hedge Funds, Innovation Management, Medical, Information Technology, B2B, Therapeutics, Media and Entertainment, Pharmaceuticals may find it worthwhile to explore potential connections with Nathalie Auber, as their portfolio suggests a familiarity and interest in this area.

Understanding Nathalie Auber’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.